Literature DB >> 19619017

In vitro activity of doripenem.

Daniel Sahm1.   

Abstract

Doripenem is a carbapenem antibiotic that covers a wide range of gram-positive and gram-negative pathogens. In vitro studies have provided insight into certain features of doripenem's activity profile that may have particular relevance in the clinical setting. For instance, in vitro data indicate that doripenem combines the intrinsic activity of meropenem against gram-negative pathogens with the intrinsic activity of imipenem against gram-positive pathogens. Also notable is the fact that the in vitro activity of doripenem against problematic gram-negative pathogens, in particular Pseudomonas aeruginosa, is potent-recent data show that the minimum concentration necessary for inhibition of 90% of all isolates (MIC(90)) of doripenem with respect to P. aeruginosa (4 microg/mL) is 2-4 times lower than the corresponding MIC(90) values of meropenem and imipenem. Furthermore, doripenem shows a limited ability to select for carbapenem-resistant mutants in vitro. Such experimental findings suggest that doripenem may represent a valuable option when carbapenem therapy is warranted for the treatment of serious infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19619017     DOI: 10.1086/599811

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

1.  Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.

Authors:  Mahesh N Samtani; Robert Flamm; Koné Kaniga; Partha Nandy
Journal:  Antimicrob Agents Chemother       Date:  2010-04-12       Impact factor: 5.191

2.  Antimicrobial resistance surveillance of doripenem in China.

Authors:  Yun Li; Yuan Lv; Feng Xue; Bo Zheng; Jian Liu; Jia Zhang
Journal:  J Antibiot (Tokyo)       Date:  2015-04-08       Impact factor: 2.649

3.  Therapeutic Drug Monitoring of Continuous Infusion Doripenem in a Pediatric Patient on Continuous Renal Replacement Therapy.

Authors:  Jeffrey J Cies; Wayne S Moore; Susan B Conley; Paul Shea; Adela Enache; Arun Chopra
Journal:  J Pediatr Pharmacol Ther       Date:  2017 Jan-Feb

4.  A focus on intra-abdominal infections.

Authors:  Massimo Sartelli
Journal:  World J Emerg Surg       Date:  2010-03-19       Impact factor: 5.469

5.  Sustained Pulmonary Delivery of a Water-Soluble Antibiotic Without Encapsulating Carriers.

Authors:  Winston Ong; Pawel Nowak; Yen Cu; Lisa Schopf; James Bourassa; Elizabeth Enlow; Samuel M Moskowitz; Hongming Chen
Journal:  Pharm Res       Date:  2015-10-27       Impact factor: 4.200

Review 6.  Resistance Trends and Treatment Options in Gram-Negative Ventilator-Associated Pneumonia.

Authors:  Nathaniel J Rhodes; Caroline E Cruce; J Nicholas O'Donnell; Richard G Wunderink; Alan R Hauser
Journal:  Curr Infect Dis Rep       Date:  2018-03-06       Impact factor: 3.725

7.  Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  Roger Sordé; Albert Pahissa; Jordi Rello
Journal:  Infect Drug Resist       Date:  2011-01-25       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.